Pipeline

liposomeIonizable Lipids & Lipid nanoparticle (LNP)nanocrystal

Liposome

Vehicle

Indication

Modality

Delivery route

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Liposome

Indication

Breast cancer

Modality

Small molecule

Delivery route

IV

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Indication

Lung cancer

Modality

Small molecule

Delivery route

IV

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Indication

Pancreatic cancer

Modality

Small molecule

Delivery route

IV

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Indication

Infection

Modality

Small molecule

Delivery route

IV

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Indication

Local anesthesia

Modality

Small molecule

Delivery route

Local injection

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Lipid Nanoparticle

Vehicle

Indication

Modality

Delivery route

Vehicle

Preclinical

Clinical

(Phase 1 and 2)

Lipid Nanoparticle

Indication

Viral infection

Modality

mRNA

Delivery route

IM

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Indication

Liver disease

Modality

Cas9 mRNA + sgRNA

Delivery route

IV

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Nanocrystal

Vehicle

Indication

Modality

Delivery route

Vehicle

Preclinical

Clinical

(Phase 1 and 2)

Nanocrystal

Indication

Mental disorder

Modality

Small molecule

Delivery route

IM

Discovery

Preclinical

Clinical

(Phase 1 and 2)

Therapeutic
Areas of Focus

Oncology
and Cancer Drug
Resistance

Multidrug resistance is responsible for over 90% of deaths in cancer patients. Treatment based on drug combinations emerges as a promising method to tackle cancer drug resistance, and drug vehicles that can deliver multiple therapeutic agents at their synergistic ratios to the tumor site are the key to desired treatment efficacy.

However, limited drug delivery systems can be utilized for combined therapeutic agent delivery, and they suffer from unavoidable drawbacks, such as low drug loading content, premature drug leakage and inferior product stability. Our liposome-based drug delivery platform is designed to address this unmet medical need by efficiently encapsulating multiple cancer drug compounds within the same liposome vehicle for synergistic therapeutic effect, and the product exhibits desired physiochemical stability and enhanced therapeutic outcome.

Pain Management

With over 70 million surgeries performed annually in the United States, postoperative pain is a pervasive issue. The prevailing method for achieving extended anesthesia, lasting multiple days, currently relies on catheter techniques employing disposable pumps or multiple injections.  These existing treatment modalities confront both technical and clinical challenges, necessitating the exploration of enhanced alternatives.  At NanoTech, our dedicated team is committed to developing liposome-based systems designed to facilitate the sustained release of local anesthetic agents, thereby achieving an extended duration of analgesia.  Our advanced delivery vehicle is capable of accommodating a substantial drug payload, ensuring a consistently adequate concentration of anesthetic agent at the nerve block site for an extended period. Our primary objective is to offer improved solutions for enhancing postoperative pain management.

Pain Management

Opportunities
in Broad Array
of Genetic Disorders

With the improved delivery specificity and efficiency, our AccuLNP® platform can carry a variety of genetic cargos to the disease site and has the potential to be applied across a wide range of genetic disorders including central nervous system (CNS), liver, and cancer.

liposome

Send us
a message

molecular networkmolecular network

Invalid name

Invalid phone number

This field is required

This field is required

This field is required

arrowarrowarrow

submit

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.